Achieve Life Sciences, Inc. (NASDAQ:ACHV) Sees Large Increase in Short Interest

Achieve Life Sciences, Inc. (NASDAQ:ACHVGet Free Report) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 701,800 shares, an increase of 9.1% from the February 29th total of 643,200 shares. Based on an average daily trading volume, of 92,000 shares, the short-interest ratio is presently 7.6 days.

Analyst Ratings Changes

Several research firms recently issued reports on ACHV. Oppenheimer reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Achieve Life Sciences in a report on Monday. Lake Street Capital decreased their price objective on shares of Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, March 5th.

Read Our Latest Stock Analysis on Achieve Life Sciences

Hedge Funds Weigh In On Achieve Life Sciences

Hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its stake in shares of Achieve Life Sciences by 75.6% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,646 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 1,570 shares in the last quarter. HRT Financial LP acquired a new position in shares of Achieve Life Sciences in the 4th quarter valued at $32,000. Morgan Stanley raised its stake in shares of Achieve Life Sciences by 437.4% in the 4th quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 11,026 shares in the last quarter. Madison Park Capital Advisors LLC acquired a new position in shares of Achieve Life Sciences in the 4th quarter valued at $41,000. Finally, Prelude Capital Management LLC acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at $49,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Achieve Life Sciences Price Performance

Shares of Achieve Life Sciences stock opened at $4.48 on Wednesday. The company has a debt-to-equity ratio of 4.02, a current ratio of 5.36 and a quick ratio of 5.36. Achieve Life Sciences has a fifty-two week low of $3.03 and a fifty-two week high of $10.30. The firm has a fifty day moving average price of $4.50 and a two-hundred day moving average price of $4.40. The company has a market cap of $94.84 million, a PE ratio of -2.93 and a beta of 1.32.

Achieve Life Sciences Company Profile

(Get Free Report)

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.

Recommended Stories

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.